FI942573A - Koostumus, joka käsittää hyytymistekijä VIII -formuloinnin, sen valmistusmenetelmä ja pinta-aktiivisen aineen käyttö stabilointiaineena - Google Patents
Koostumus, joka käsittää hyytymistekijä VIII -formuloinnin, sen valmistusmenetelmä ja pinta-aktiivisen aineen käyttö stabilointiaineena Download PDFInfo
- Publication number
- FI942573A FI942573A FI942573A FI942573A FI942573A FI 942573 A FI942573 A FI 942573A FI 942573 A FI942573 A FI 942573A FI 942573 A FI942573 A FI 942573A FI 942573 A FI942573 A FI 942573A
- Authority
- FI
- Finland
- Prior art keywords
- stabilizer
- preparation
- composition
- surfactant
- factor viii
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
- Y10S530/83—Plasma; serum
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Detergent Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9202878A SE9202878D0 (sv) | 1992-10-02 | 1992-10-02 | Protein formulation |
SE9202878 | 1992-10-02 | ||
SE9300793 | 1993-03-10 | ||
SE9301580A SE9301580D0 (sv) | 1993-05-07 | 1993-05-07 | Protein formulation |
SE9301580 | 1993-05-07 | ||
SE9302006 | 1993-06-11 | ||
SE9302006A SE9302006D0 (sv) | 1992-10-02 | 1993-06-11 | Protein formulation |
PCT/SE1993/000793 WO1994007510A1 (en) | 1992-10-02 | 1993-10-01 | Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer |
Publications (3)
Publication Number | Publication Date |
---|---|
FI942573A0 FI942573A0 (fi) | 1994-06-01 |
FI942573A true FI942573A (fi) | 1994-06-01 |
FI111443B FI111443B (fi) | 2003-07-31 |
Family
ID=27355693
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI942573A FI111443B (fi) | 1992-10-02 | 1994-06-01 | Valmistusmenetelmä koostumukselle rekombinantti-hyytymistekijän VIII stabiloimiseksi |
Country Status (19)
Country | Link |
---|---|
US (2) | US5733873A (fi) |
EP (3) | EP1652534A3 (fi) |
JP (1) | JP3905921B2 (fi) |
KR (1) | KR100303872B1 (fi) |
AT (2) | ATE316981T1 (fi) |
CA (1) | CA2124690C (fi) |
CZ (1) | CZ290342B6 (fi) |
DE (2) | DE69333974T2 (fi) |
DK (1) | DK0627924T3 (fi) |
ES (1) | ES2154650T3 (fi) |
FI (1) | FI111443B (fi) |
GR (1) | GR3035472T3 (fi) |
HU (2) | HU220194B (fi) |
MX (1) | MX9306133A (fi) |
NO (1) | NO942033D0 (fi) |
NZ (1) | NZ256921A (fi) |
PT (1) | PT627924E (fi) |
SK (1) | SK282483B6 (fi) |
WO (1) | WO1994007510A1 (fi) |
Families Citing this family (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100303872B1 (ko) * | 1992-10-02 | 2001-11-22 | 크리스터 발스트룀, 프레드릭 베르그, 하랄트 알름 | 응고인자ⅷ제형을포함하는조성물,이것의제조방법및안정화제로서의계면활성제의사용방법 |
SE504074C2 (sv) † | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
US6288030B1 (en) * | 1993-12-22 | 2001-09-11 | Amgen Inc. | Stem cell factor formulations and methods |
US6242417B1 (en) * | 1994-03-08 | 2001-06-05 | Somatogen, Inc. | Stabilized compositions containing hemoglobin |
IL113010A0 (en) * | 1994-03-31 | 1995-10-31 | Pharmacia Ab | Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration |
US5514781A (en) * | 1994-04-11 | 1996-05-07 | Bayer Corporation | Use of azoles as virucidal agents in solutions of biologically active proteins |
US6372716B1 (en) * | 1994-04-26 | 2002-04-16 | Genetics Institute, Inc. | Formulations for factor IX |
SE9403915D0 (sv) * | 1994-11-14 | 1994-11-14 | Annelie Almstedt | Process A |
SE503424C2 (sv) * | 1994-11-14 | 1996-06-10 | Pharmacia Ab | Process för rening av rekombinant koagulationsfaktor VIII |
US7253262B2 (en) | 1995-01-19 | 2007-08-07 | Quandrant Drug Delivery Limited | Dried blood factor composition comprising trehalose |
US7244824B2 (en) | 1995-01-19 | 2007-07-17 | Quadrant Drug Delivery Limited | Dried blood factor composition comprising trehalose |
GB9501040D0 (en) | 1995-01-19 | 1995-03-08 | Quadrant Holdings Cambridge | Dried composition |
SE9501189D0 (sv) * | 1995-03-31 | 1995-03-31 | Pharmacia Ab | Protein formulation |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
AUPN801296A0 (en) * | 1996-02-12 | 1996-03-07 | Csl Limited | Stabilised growth hormone formulation and method of preparation thereof |
US7560107B2 (en) | 1996-06-26 | 2009-07-14 | Emory University | Modified factor VIII |
US5763401A (en) * | 1996-07-12 | 1998-06-09 | Bayer Corporation | Stabilized albumin-free recombinant factor VIII preparation having a low sugar content |
EP0852951A1 (de) * | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
US6475725B1 (en) | 1997-06-20 | 2002-11-05 | Baxter Aktiengesellschaft | Recombinant cell clones having increased stability and methods of making and using the same |
EP1154796B1 (en) * | 1999-02-22 | 2007-06-20 | University of Connecticut | Novel albumin-free factor viii formulations |
US20060099685A1 (en) * | 1999-04-15 | 2006-05-11 | Yallop Christopher A | Recombinant expression of factor VIII in human cells |
EP1194161B1 (en) | 1999-07-13 | 2005-11-23 | Biovitrum Ab | Stable factor viii compositions |
US6413537B1 (en) | 2000-03-10 | 2002-07-02 | Wisconsin Alumni Research Foundation | Nystatin formulation having reduced toxicity |
GB0207092D0 (en) | 2002-03-26 | 2002-05-08 | Sod Conseils Rech Applic | Stable pharmaceutical composition containing factor VIII |
AU2003293543A1 (en) * | 2002-12-13 | 2004-07-09 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
JP2007505147A (ja) | 2003-09-12 | 2007-03-08 | アンティジェニクス インコーポレーテッド | 単純ヘルペスウイルス感染の治療および予防用ワクチン |
EP1750733B1 (en) | 2004-05-03 | 2013-12-11 | Emory University | METHOD OF ADMINISTERING PORCINE B-DOMAINLESS fVIII |
KR100624013B1 (ko) * | 2004-06-25 | 2006-09-19 | 주식회사 녹십자홀딩스 | 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제 |
GB2416122A (en) | 2004-07-12 | 2006-01-18 | Ipsen Ltd | Botulinum neurotoxin composition |
KR101654011B1 (ko) | 2004-11-12 | 2016-09-05 | 바이엘 헬스케어 엘엘씨 | Fviii의 부위 지향 변형 |
DK1835938T3 (da) | 2004-12-27 | 2013-11-04 | Baxter Int | Polymer-von Willebrand-faktor-konjugater |
AU2006239117A1 (en) | 2005-04-28 | 2006-11-02 | Novo Nordisk Health Care Ag | A closed container comprising an activated factor VII polypeptide, processes for the preparation of the same, and a kit and a method for use of the kit |
WO2007031933A2 (en) | 2005-09-12 | 2007-03-22 | Actelion Pharmaceuticals Ltd | Stable pharmaceutical composition comprising a pyrimidine-sulfamide |
US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
US7645860B2 (en) * | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
JP2009532351A (ja) | 2006-03-31 | 2009-09-10 | バクスター・インターナショナル・インコーポレイテッド | ペグ化第viii因子 |
US7982010B2 (en) * | 2006-03-31 | 2011-07-19 | Baxter International Inc. | Factor VIII polymer conjugates |
US7985839B2 (en) * | 2006-03-31 | 2011-07-26 | Baxter International Inc. | Factor VIII polymer conjugates |
PT2101821E (pt) | 2006-12-15 | 2014-10-03 | Baxter Int | Fator conjugado viia-ácido (poli)siálico com prolongamento do tempo de meia vida in vivo |
CN103990116A (zh) | 2007-04-26 | 2014-08-20 | 拜尔健康护理有限责任公司 | 稳定用于冷冻储藏的重组蛋白液体溶液的方法 |
EP2574676B1 (en) | 2007-12-27 | 2017-08-30 | Baxalta GmbH | Cell culture processes |
EP2113564A1 (en) * | 2008-05-01 | 2009-11-04 | Arecor Limited | Protein formulation |
AU2009284113B2 (en) | 2008-08-21 | 2015-05-14 | Octapharma Ag | Recombinantly produced human factor VIII and IX |
WO2010026186A1 (en) * | 2008-09-03 | 2010-03-11 | Octapharma Ag | New protecting compositions for recombinantly produced factor viii |
WO2010045321A2 (en) * | 2008-10-15 | 2010-04-22 | Baxter International Inc. | Pegylation of recombinant blood coagulation factors in the presence of bound antibodies |
BRPI0921429B1 (pt) | 2008-11-07 | 2022-07-12 | Takeda Pharmaceutical Company Limited | Formulação farmacêutica liofilizada estável, e, método para preparar um fator liofilizado estável |
DK3332805T3 (da) | 2008-12-31 | 2022-05-16 | Revance Therapeutics Inc | Injicerbare botulinumtoksinformuleringer |
WO2010091122A1 (en) | 2009-02-03 | 2010-08-12 | Amunix, Inc. | Extended recombinant polypeptides and compositions comprising same |
TWI626057B (zh) | 2009-06-09 | 2018-06-11 | 普龍製藥有限責任公司 | 血紅素組成物 |
US10172949B2 (en) | 2009-06-09 | 2019-01-08 | Prolong Pharmaceuticals, LLC | Hemoglobin compositions |
US10172950B2 (en) | 2009-06-09 | 2019-01-08 | Prolong Pharmaceuticals, LLC | Hemoglobin compositions |
BRPI1015938A2 (pt) | 2009-06-25 | 2016-09-27 | Revance Therapeutics Inc | formulações da toxina botulínica livre de albumina |
US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
CA2769244A1 (en) | 2009-07-27 | 2011-02-03 | Lipoxen Technologies Limited | Glycopolysialylation of non-blood coagulation proteins |
EP2459224B1 (en) | 2009-07-27 | 2016-06-01 | Baxalta GmbH | Blood coagulation protein conjugates |
RU2744370C2 (ru) | 2009-07-27 | 2021-03-05 | Баксалта Инкорпорейтед | Конъюгаты белков свертывания крови |
US20120263701A1 (en) | 2009-08-24 | 2012-10-18 | Volker Schellenberger | Coagulation factor vii compositions and methods of making and using same |
GB0915480D0 (en) | 2009-09-04 | 2009-10-07 | Arecor Ltd | Stable formulation of factor viii |
US8765432B2 (en) | 2009-12-18 | 2014-07-01 | Oligasis, Llc | Targeted drug phosphorylcholine polymer conjugates |
RS58900B1 (sr) | 2010-07-30 | 2019-08-30 | Baxalta GmbH | Nukleofilni katalizator za vezivanje oksima |
DK2635297T3 (da) | 2010-11-05 | 2019-05-06 | Baxalta GmbH | En ny variant af antihæmofil faktor viii, der har en øget specifik aktivitet |
AU2011343813B2 (en) | 2010-12-15 | 2015-05-21 | Takeda Pharmaceutical Company Limited | Eluate collection using conductivity gradient |
KR20130125789A (ko) * | 2010-12-16 | 2013-11-19 | 노보 노르디스크 에이/에스 | 수성 인자ⅷ 용액 |
HUE049352T2 (hu) | 2010-12-22 | 2020-09-28 | Baxalta GmbH | Anyagok és módszerek egy vízoldható zsírsavszármazéknak egy fehérjéhez való konjugálására |
LT2814840T (lt) | 2012-02-15 | 2020-02-25 | Bioverativ Therapeutics Inc. | Faktoriaus viii kompozicijos ir jų gavimo ir naudojimo būdai |
EP2822577B1 (en) | 2012-02-15 | 2019-02-06 | Bioverativ Therapeutics Inc. | Recombinant factor viii proteins |
AU2013204754C1 (en) | 2012-05-16 | 2018-10-11 | Takeda Pharmaceutical Company Limited | Nucleophilic Catalysts for Oxime Linkage |
US9212357B2 (en) | 2012-12-03 | 2015-12-15 | Omrix Biopharmaceuticals Ltd. | Thrombin solution and methods of use thereof |
JP6330026B2 (ja) * | 2013-03-15 | 2018-05-23 | バイオベラティブ セラピューティクス インコーポレイテッド | 第viii因子ポリペプチド製剤 |
UY35463A (es) | 2013-03-15 | 2014-10-31 | Biogen Idec Inc | Formulaciones de polipéptido fc-factor ix. |
US9700486B2 (en) | 2013-04-24 | 2017-07-11 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
EP3033097B1 (en) | 2013-08-14 | 2021-03-10 | Bioverativ Therapeutics Inc. | Factor viii-xten fusions and uses thereof |
SI3041513T1 (sl) | 2013-09-08 | 2020-11-30 | Kodiak Sciences Inc. | Zwitterionski polimerni konjugati faktorja VIII |
KR20230136616A (ko) | 2014-02-04 | 2023-09-26 | 바이오젠 엠에이 인코포레이티드 | 번역 후 변형을 강화시키기 위한 통류 방식 양이온교환 크로마토그래피의 용도 |
KR102385372B1 (ko) | 2014-03-24 | 2022-04-11 | 바이오버라티브 테라퓨틱스 인크. | 동결건조된 ix 인자 제형 |
WO2015149144A2 (en) * | 2014-04-01 | 2015-10-08 | Advantech Bioscience Farmacêutica Ltda. | Stabilization of factor viii without calcium as an excipient |
AU2015240353A1 (en) * | 2014-04-01 | 2016-11-17 | Advantech Bioscience Farmaceutica Ltda. | Stable Factor VIII formulations with low sugar-glycine |
WO2016012595A1 (en) * | 2014-07-25 | 2016-01-28 | Csl Behring Gmbh | Improved factor viii preparations suitable for therapeutic use and processes to obtain these |
PL3177317T3 (pl) * | 2014-08-04 | 2020-07-27 | Csl Limited | Formulacja czynnika viii |
MA40864A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères |
SG10201912485PA (en) | 2015-05-13 | 2020-02-27 | Agenus Inc | Vaccines for treatment and prevention of cancer |
AR104847A1 (es) | 2015-06-17 | 2017-08-16 | Lilly Co Eli | Formulación de anticuerpo anti-cgrp |
AU2016301303B2 (en) | 2015-08-03 | 2021-10-07 | Bioverativ Therapeutics Inc. | Factor IX fusion proteins and methods of making and using same |
US20190209475A1 (en) * | 2015-11-05 | 2019-07-11 | Novo Nordisk A/S | FVIII Formulation |
EP3167877A1 (en) | 2015-11-12 | 2017-05-17 | Bayer Pharma Aktiengesellschaft | Method for the production of freeze-dried pellets comprising factor viii |
TW201731869A (zh) | 2015-12-03 | 2017-09-16 | 百克莎塔股份有限公司 | 具有延長之半衰期及降低之配位體結合性質的因子viii |
CA3078625C (en) | 2017-10-09 | 2023-01-17 | Terumo Bct Biotechnologies, Llc | Lyophilization container and method of using same |
CN112218883A (zh) | 2018-04-26 | 2021-01-12 | 艾吉纳斯公司 | 热休克蛋白结合肽组合物及其使用方法 |
AU2019270184A1 (en) | 2018-05-18 | 2020-11-26 | Bioverativ Therapeutics Inc. | Methods of treating hemophilia A |
CA3130668A1 (en) | 2019-03-14 | 2020-12-03 | Terumo Bct Biotechnologies, Llc | Multi-part lyophilization container and method of use |
CN114072420B (zh) | 2019-07-04 | 2024-06-11 | 康诺贝林伦瑙有限公司 | 用于增加凝血因子viii的体外稳定性的截短的血管性血友病因子(vwf) |
JP2022553640A (ja) | 2019-10-10 | 2022-12-26 | コディアック サイエンシーズ インコーポレイテッド | 眼障害を処置する方法 |
JP2023527171A (ja) * | 2020-05-22 | 2023-06-27 | アール-ファーム・オーバーシーズ・インコーポレイテッド | IL-1βのIL1-R1由来のインヒビターおよびその使用 |
US20220380439A1 (en) | 2020-11-09 | 2022-12-01 | Takeda Pharmaceutical Company Limited | Purification of fviii from plasma using silicon oxide adsorption |
AU2022298798A1 (en) * | 2021-06-23 | 2024-02-08 | Bioverativ Therapeutics Inc. | Formulations of factor viii chimeric proteins and uses thereof |
AU2022366974A1 (en) * | 2021-10-15 | 2024-05-30 | Bioverativ Therapeutics Inc. | Formulations of factor viii chimeric proteins and uses thereof |
CN115554418B (zh) * | 2022-11-22 | 2023-04-14 | 四川至善唯新生物科技有限公司 | 一种重组腺相关病毒载体的药物组合物及其用途 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4165370A (en) * | 1976-05-21 | 1979-08-21 | Coval M L | Injectable gamma globulin |
US4783441A (en) * | 1979-04-30 | 1988-11-08 | Hoechst Aktiengesellschaft | Aqueous protein solutions stable to denaturation |
DE3176491D1 (en) * | 1980-03-05 | 1987-11-26 | Miles Lab | Pasteurized therapeutically active protein compositions |
US4481189A (en) * | 1982-04-14 | 1984-11-06 | New York Blood Center Inc. | Process for preparing sterilized plasma and plasma derivatives |
US4597966A (en) * | 1985-01-09 | 1986-07-01 | Ortho Diagnostic Systems, Inc. | Histidine stabilized immunoglobulin and method of preparation |
SE8501050D0 (sv) * | 1985-03-05 | 1985-03-05 | Kabivitrum Ab | Biologically active fragments of human antihemophilic factor and method for preparation thereof |
US4758657A (en) * | 1985-07-11 | 1988-07-19 | Armour Pharmaceutical Company | Method of purifying Factor VIII:C |
CA1292686C (en) * | 1986-10-27 | 1991-12-03 | Ze'ev Shaked | Pharmaceutical compositions of recombinant interleukin-2 and formulation process |
US4877608A (en) * | 1987-11-09 | 1989-10-31 | Rorer Pharmaceutical Corporation | Pharmaceutical plasma protein formulations in low ionic strength media |
FR2630115B1 (fr) * | 1988-04-14 | 1994-10-28 | Merieux Inst | Procede de stabilisation des solutions d'albumine humaine et solution obtenue |
US5096885A (en) * | 1988-04-15 | 1992-03-17 | Genentech, Inc. | Human growth hormone formulation |
US4996047A (en) * | 1988-11-02 | 1991-02-26 | Richardson-Vicks, Inc. | Sustained release drug-resin complexes |
ATE108326T1 (de) * | 1989-01-30 | 1994-07-15 | Corint Ltd | Wässerige desmopressin-cmc enthaltende arzneizubereitung. |
SE465222C5 (sv) * | 1989-12-15 | 1998-02-10 | Pharmacia & Upjohn Ab | Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning |
DE4001451A1 (de) * | 1990-01-19 | 1991-08-01 | Octapharma Ag | Stabile injizierbare loesungen von faktor viii und faktor ix |
DE4111393A1 (de) * | 1991-04-09 | 1992-10-15 | Behringwerke Ag | Stabilisierte faktor viii-praeparationen |
KR100303872B1 (ko) * | 1992-10-02 | 2001-11-22 | 크리스터 발스트룀, 프레드릭 베르그, 하랄트 알름 | 응고인자ⅷ제형을포함하는조성물,이것의제조방법및안정화제로서의계면활성제의사용방법 |
-
1993
- 1993-10-01 KR KR1019940701858A patent/KR100303872B1/ko not_active IP Right Cessation
- 1993-10-01 DE DE69333974T patent/DE69333974T2/de not_active Expired - Lifetime
- 1993-10-01 CZ CZ19941328A patent/CZ290342B6/cs not_active IP Right Cessation
- 1993-10-01 HU HU9401382A patent/HU220194B/hu unknown
- 1993-10-01 MX MX9306133A patent/MX9306133A/es active IP Right Grant
- 1993-10-01 AT AT99121997T patent/ATE316981T1/de active
- 1993-10-01 PT PT93923080T patent/PT627924E/pt unknown
- 1993-10-01 AT AT93923080T patent/ATE198277T1/de active
- 1993-10-01 NZ NZ256921A patent/NZ256921A/en not_active IP Right Cessation
- 1993-10-01 EP EP06001883A patent/EP1652534A3/en not_active Withdrawn
- 1993-10-01 EP EP93923080A patent/EP0627924B1/en not_active Expired - Lifetime
- 1993-10-01 SK SK659-94A patent/SK282483B6/sk not_active IP Right Cessation
- 1993-10-01 JP JP50895794A patent/JP3905921B2/ja not_active Expired - Lifetime
- 1993-10-01 US US08/244,266 patent/US5733873A/en not_active Expired - Lifetime
- 1993-10-01 DE DE69329795T patent/DE69329795T2/de not_active Expired - Lifetime
- 1993-10-01 ES ES93923080T patent/ES2154650T3/es not_active Expired - Lifetime
- 1993-10-01 EP EP99121997A patent/EP1016673B1/en not_active Expired - Lifetime
- 1993-10-01 WO PCT/SE1993/000793 patent/WO1994007510A1/en active IP Right Grant
- 1993-10-01 CA CA002124690A patent/CA2124690C/en not_active Expired - Lifetime
- 1993-10-01 DK DK93923080T patent/DK0627924T3/da active
-
1994
- 1994-06-01 FI FI942573A patent/FI111443B/fi not_active IP Right Cessation
- 1994-06-01 NO NO942033A patent/NO942033D0/no not_active Application Discontinuation
-
1995
- 1995-06-28 HU HU95P/P00473P patent/HU211670A9/hu unknown
-
1997
- 1997-05-27 US US08/863,198 patent/US5919766A/en not_active Expired - Lifetime
-
2001
- 2001-02-23 GR GR20010400311T patent/GR3035472T3/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI942573A (fi) | Koostumus, joka käsittää hyytymistekijä VIII -formuloinnin, sen valmistusmenetelmä ja pinta-aktiivisen aineen käyttö stabilointiaineena | |
ATE121125T1 (de) | Giessbare sulfon- peroxycarbonsäurezusammensetzung. | |
DE69014684D1 (de) | Biologisch abbaubare Polyphosphoester. | |
FI920023A0 (fi) | Heteroarylpiperazinfoereningar som antipsykotiska aemnen. | |
FI924424A (fi) | Hjaertskyddande tokoferolanaloger | |
BR9301641A (pt) | Processo para produzir uma preparacao de fator viii,altamente purificada e uso | |
ES2146606T3 (es) | Metodo para limpiar alfombras. | |
FI892222A (fi) | Peptidalkoholer med antikoagulantverkan. | |
CA2015919A1 (fr) | Composition nettoyante | |
ATE190498T1 (de) | Stabile, pharmazeutische zusammensetzungen die hybrid alpha-interferon enthalten | |
NO904359D0 (no) | Zeolitt-suspensjoner. | |
ATE132032T1 (de) | Kosmetische zusammensetzung | |
DE68908620D1 (de) | Primycin enthaltende Arzneimittelzusammensetzungen. | |
ATE157959T1 (de) | Indanderivate | |
IL103856A0 (en) | Aminoalkyl-substituted 5,6-dihydro-dibenz(b,e)azepin-6,11-dione-11-oximes,their preparation and pharmaceutical compositions containing them | |
DE3577970D1 (de) | Desinfektionszusammensetzungen. | |
EE03171B1 (et) | Hüübimistegur VIII vormi sisaldav kompositsioon, selle valmistamismeetod ning pindaktiivse aine kasutamine stabilisaatorina | |
DE69428127D1 (de) | Schädlingsbekämpfungsmittel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB | Transfer or assigment of application |
Owner name: GENETICS INSTITUTE, INC. |
|
GB | Transfer or assigment of application |
Owner name: GENETICS INSTITUTE, INC. |
|
MA | Patent expired |